Open Label Extension Study (OLE)

OLE is a drug trial for symptomatic individuals conducted in collaboration with AstraZeneca LP in Wayne, Pennsylvania.

Overview

The purpose of this trial is to assess the safety of long-term (28-month) exposure to remacemide hydrochloride (an investigational medication) in people with Huntington's Disease, as well as analyse the effect of remacemide hydrochloride on chorea, mood and mental functioning.

Design

• Open-label (i.e. all subjects take the active drug)

• Single dose (600 mg/day) study

• 350 participants in Canada and the US (7 at UBC)

Eligibility Criteria

To participate in this trial, patients:

• Must have completed CARE-HD or START-HD

• Be 14 years or older (legal guardian required for minors)

Outcome

The study was terminated because CARE-HD results showed that remacemide does not benefit HD patients.

Site Investigation Team

• Dr. Blair Leavitt (site investigator)

• Joji Decolongon (site co-ordinator)

For more information please call +1 (604) 822-7928 or e-mail Joji Decolongon at joji@cmmt.ubc.ca.